Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment

NCT05753930 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.

NCT NCT05753930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05753930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment
Lead sponsor
Hansa Biopharma AB
Phase
Phase 2
Overall status
Recruiting
Start date
June 2, 2023
Completion date
August 31, 2031
Enrollment
10 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation in highly sensitized patients